02.18.15
Dr. Perry Calias has been appointed chief scientific officer at Pharming Group NV. Dr. Calias will have overall responsibility for the company's new Enzyme Replacement Therapy (ERT) programs, driving scientific milestones, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the company.
With the recent acquisition of TRM SASU, Pharming is expanding its validated platform for the production of recombinant human proteins, and also plans to open a small R&D office in Boston, MA. Dr. Calias will be based in Boston and will also spend time in Paris and Leiden.
Dr. Calias previously served as senior director for Shire within the Human Genetic Therapeutics division, where he supported the investigational effort for the intrathecal administration of recombinant enzymes for the treatment of the central nervous system (CNS) disorders associated with lysosomal storage diseases. Dr. Calias also held various R&D positions at BBB Technologies, EyeGate Pharmaceuticals, Eyetech Pharmaceuticals, Draper Laboratories and Genzyme Corp.
With the recent acquisition of TRM SASU, Pharming is expanding its validated platform for the production of recombinant human proteins, and also plans to open a small R&D office in Boston, MA. Dr. Calias will be based in Boston and will also spend time in Paris and Leiden.
Dr. Calias previously served as senior director for Shire within the Human Genetic Therapeutics division, where he supported the investigational effort for the intrathecal administration of recombinant enzymes for the treatment of the central nervous system (CNS) disorders associated with lysosomal storage diseases. Dr. Calias also held various R&D positions at BBB Technologies, EyeGate Pharmaceuticals, Eyetech Pharmaceuticals, Draper Laboratories and Genzyme Corp.